Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Subscribe
Login
Password
Password
Remember me
Forgot password?
Close login form
Home
Hospira
Hospira
Activities:
Drug Delivery
Pharmaceutical
Trending Articles
Poolbeg Pharma trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme
Poolbeg will act as the lead business partner, alongside Johnson & Johnson and other partners, on the University of Manchester and The Christie NHS Foundation Trust research...
Manufacturing Chemist Stand Side with Piramal Pharma Solutions
We discover what exhibitors at CPHI 2025 are showcasing LIVE!
SGS achieves breakthrough in infectious disease research with launch of novel RSV A-strain
Derived from a 2015 circulating strain, SGS's novel RSV-A challenge agent offers a closer match to circulating RSV viruses than strains currently used in clinical research
One in four European pharma companies at risk of regulatory breaches according to NSF research
The independent survey exposed significant gaps in quality systems, supply chain oversight and data integration, just as EU GMP regulations continue to tighten
IWK introduces machine to produce 100% cardboard blister packaging
CABLIblue 870 features innovative “card-to-card” technology for recyclable, fiber-based blisters
Upcoming event
From powder to granules: a deep dive into wet granulation methods
14 January 2026 | Virtual
See all
Related Content
Regulatory
FDA cautions Pfizer subsidiary in India in quality control warning letter
The letter is the result of an inspection at Hospira Healthcare India that identified GMP violations in quality control, data integrity, and microbial control
Drug Delivery
Mylan and Hospira voluntarily recall injectables
Glass and copper salts were found in the companies’ injectable medications but no adverse reactions have been reported as yet
Regulatory
Brussels explains why it approved Pfizer/Hospira deal
Pfizer made a commitment to remove possible product overlaps between the two companies
Regulatory
Hospira calls for biosimilars to have same name as biologicals
Different names for a biologic and the biosimilar medicine patterned on that biologic could create confusion among clinicians
Research & Development
Hospira and Pfenex link up to develop Lucentis biosimilar
Pfenex will receive US$51m upfront once the collaboration receives antitrust approval
Drug Delivery
Pfizer to acquire Hospira
Pfizer and Hospira have entered into a definitive merger agreement under which Pfizer will acquire Hospira
Manufacturing
Opinion: Still not getting it right
The future for pharma development is bright, but there are still too many potentially dangerous recalls in the manufacturing sector
Subscribe now